PACE-CME

The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?

The high risk diabetes patient What is the need for novel approaches to reduce cardiovascular and renal risk
RestartResume
10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain
  • Overview

    Luis M Ruilope, MD looks at the evidence showing that currently available therapies leave room for improvement in the reduction of CV events in patients with diabetes and chronic kidney disease.

  • Educational information

    • To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
    • To understand the origin of the high residual cardiovascular risk in patients with diabetes and kidney disease
    • To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD and CKD
    • To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management
  • Disclosures

    • Luis M Ruilope, MD , Hospital 12 de Octubre Madrid, Spain
  • Funding

    The symposium was supported by an unrestricted educational grant from Resverlogix Corp

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free